Charles River Laboratories
CRL
$277.00
+3.56%
Charles River Laboratories International, Inc. is a leading provider of drug discovery, non-clinical development, and manufacturing support services, operating across the pharmaceutical and biotechnology industries. The company is a market leader in animal research models and preclinical services, with a distinct competitive identity as a comprehensive end-to-end partner for drug development. Currently, the stock is drawing attention due to a strong recovery in demand for its services, evidenced by a robust recent earnings report and a significant upward revision in its stock price, while investors debate the sustainability of this growth amid broader biotech funding cycles.…
CRL
Charles River Laboratories
$277.00
Investment Opinion: Should I buy CRL Today?
Rating: Hold. The stock has strong momentum and a positive analyst consensus, but the current price exceeds the average analyst target, suggesting limited upside. The thesis is that CRL is a quality company with a strong market position, but the recent earnings volatility and high valuation warrant caution. Investors should wait for a pullback or confirmation of sustained earnings growth before adding positions.
Sign up to view all
CRL 12-Month Price Forecast
The AI model assesses CRL as neutral, as the strong price momentum and positive analyst sentiment are offset by sluggish revenue growth and a stock price above the average target. The key factor is whether the earnings recovery materializes as expected; if it does, the stock could continue to rise, but if not, a correction is likely. The model would upgrade to bullish if Q2 earnings show accelerating growth and the stock pulls back to a more reasonable valuation, or downgrade to bearish if revenue growth turns negative or the company issues weak guidance.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Charles River Laboratories's 12-month outlook, with a consensus price target around $270.86 and implied upside of -2.2% versus the current price.
Average Target
$270.86
0 analysts
Implied Upside
-2.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$145 - $310
Analyst target range
The stock is covered by 14 analysts, with a consensus recommendation of 'buy' and a mean recommendation score of 1.81 (where 1 is strong buy and 5 is sell). The average target price is $228.50, which is 13.9% below the current price of $265.51, indicating that the stock has surpassed analyst expectations. The target range is $135.00 to $264.00, with the high target near the current price, suggesting limited upside potential according to the most bullish analyst. The low target of $135.00 implies a 49% downside, reflecting significant bearish risk. Recent ratings actions have been positive, with Morgan Stanley upgrading from Equal Weight to Overweight in June 2026 and CLSA upgrading from Hold to Outperform in May 2026, while Mizuho and UBS maintain Neutral stances. The wide target spread indicates high uncertainty about the stock's future performance, but the recent momentum and positive earnings surprise may lead to upward target revisions.
Bulls vs Bears: CRL Investment Factors
CRL presents a mixed picture: strong price momentum and positive analyst sentiment are offset by recent losses and sluggish revenue growth. The bull case rests on expectations of an earnings recovery, supported by a low PEG ratio and recent upgrades, while the bear case highlights the stock's premium valuation and the risk of disappointment if growth fails to materialize. Currently, the evidence slightly favors the bulls given the strong technical trend and improving analyst outlook, but the key tension is whether the earnings recovery will be robust enough to justify the current price. If Q2 earnings confirm a strong rebound, the stock could continue higher; if not, a correction toward the average target is likely.
Bullish
- Strong price momentum and relative strength: CRL has surged 76.6% over the past year and 40.3% over six months, with a relative strength of 55.2% versus the S&P 500 over one year. The stock is trading at 99.2% of its 52-week high, indicating robust investor confidence and a strong uptrend.
- Undervalued on forward earnings and PEG: With a forward PE of 21.45x and a PEG ratio of 0.045, the stock appears undervalued relative to its expected earnings growth. Analysts estimate EPS of $15.29 for the next fiscal year, implying a significant earnings recovery from the current negative trailing EPS.
- Positive analyst sentiment and recent upgrades: The consensus recommendation is 'buy' with a mean score of 1.81, and recent upgrades from Morgan Stanley (Equal Weight to Overweight) and CLSA (Hold to Outperform) signal improving sentiment. These actions suggest analysts see upside potential beyond the current price.
- Diversified revenue streams across segments: Revenue is well-diversified: Discovery and Safety Assessment ($596.9M), Research Models and Services ($208.4M), and Manufacturing Support ($190.5M) in Q1 2026. This reduces reliance on any single product line and provides stability across drug development phases.
Bearish
- Recent net loss and negative EPS: Q1 2026 reported a net loss of -$14.84 million, a sharp reversal from a $25.47 million profit in Q1 2025, driven by a -$149.8 million other expense. Trailing EPS is -$0.014, making the trailing PE meaningless and raising concerns about earnings quality.
- Stock trades above average analyst target: The current price of $265.51 is 13.9% above the average analyst target of $228.50, and even the high target of $264.00 is below the current price. This suggests the stock may have outpaced fundamental expectations, limiting near-term upside.
- High valuation multiples relative to history: The PS ratio of 2.51x is near the historical low, but the EV/EBITDA of 31.5x is elevated, and the forward PE of 21.45x is not cheap. If earnings recovery stalls, the stock could face multiple compression.
- Revenue growth is sluggish: Q1 2026 revenue grew only 1.2% YoY, and TTM revenue is roughly flat. This modest growth may not justify the recent price surge, especially if the biotech funding environment remains challenging.
CRL Technical Analysis
The stock is in a strong uptrend, with a 1-year price change of +76.6% and currently trading at $265.51, which is 99.2% of its 52-week range (low: $144.26, high: $267.74). This positioning near the highs indicates robust momentum and investor confidence, though it also suggests the stock may be overextended in the short term. The 6-month change of +40.3% and YTD change of +31.2% confirm the sustained upward trajectory, with the stock outperforming the S&P 500 significantly over all timeframes.
Beta
1.38
1.38x market volatility
Max Drawdown
-33.9%
Largest decline past year
52-Week Range
$144-$277
Price range past year
Annual Return
+86.2%
Cumulative gain past year
| Period | CRL Return | S&P 500 |
|---|---|---|
| 1m | +18.7% | +2.4% |
| 3m | +64.2% | +4.7% |
| 6m | +66.9% | +11.7% |
| 1y | +86.2% | +21.3% |
| ytd | +36.8% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CRL Fundamental Analysis
Revenue for the latest quarter (Q1 2026) was $995.83 million, up 1.2% year-over-year, showing modest growth after a period of stagnation. The company's revenue has been relatively flat over the past year, with Q1 2026 revenue slightly above Q1 2025's $984.17 million, but below Q2 2025's $1.032 billion. The Discovery and Safety Assessment segment is the largest, contributing $596.9 million, followed by Manufacturing Support at $190.5 million and Research Models and Services at $208.4 million, indicating a diversified revenue base. However, the company reported a net loss of -$14.84 million in Q1 2026, a sharp reversal from the $25.47 million profit in Q1 2025, driven by a -$149.8 million other expense, which is a concern for profitability.
Quarterly Revenue
$995830000.0B
2026-03
Revenue YoY Growth
+1.2%
YoY Comparison
Gross Margin
28.1%
Latest Quarter
Free Cash Flow
$391290000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CRL Overvalued?
Given the negative trailing EPS of -$0.014, the PE ratio is not meaningful, so we use the price-to-sales (PS) ratio as the primary valuation metric. The current PS ratio is 2.51x, based on a market cap of $10.09 billion and TTM revenue of approximately $4.02 billion. The forward PE is 21.45x, implying the market expects a significant earnings recovery, which is also reflected in the PEG ratio of 0.045, suggesting the stock is undervalued relative to its expected growth. Compared to the industry average PS ratio of 3.83x (EV/Sales), CRL trades at a 34% discount, which may indicate undervaluation or lower growth expectations. Historically, the stock's PS ratio has ranged from 7.8x to 25.8x over the past five years, and the current 2.51x is near the historical low, suggesting the market is pricing in pessimistic scenarios, but the recent earnings beat and upward guidance may justify a re-rating.
PE
-70.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 15x~52x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
31.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant: CRL reported a net loss of -$14.84 million in Q1 2026, reversing a profit from the prior year, due to a -$149.8 million other expense. The company's debt-to-equity ratio of 0.97 indicates high leverage, and interest expenses of $26.7 million in Q1 2026 could rise if rates stay high. Operating margin improved to 12.6% in Q1, but the negative net margin of -3.6% TTM shows that non-operating items are hurting profitability. Free cash flow of $391.3 million provides some cushion, but the company's ability to service debt and invest in growth depends on a sustained earnings recovery.
FAQ
The key risks are: 1) Financial risk: high debt-to-equity of 0.97 and negative net income in Q1 2026, which could lead to liquidity issues if earnings don't recover. 2) Competitive risk: the company faces competition from other CROs and in-house R&D by pharma companies, which could pressure margins. 3) Macro risk: the stock has a beta of 1.1, so it is sensitive to market downturns, and a biotech funding slowdown could reduce demand. 4) Company-specific risk: regulatory changes regarding animal testing could impact the Research Models segment. The most severe risk is a prolonged earnings recession, which could drive the stock down to the 52-week low of $144.26, a 45% downside.
The 12-month forecast is mixed: the bull case (25% probability) targets $280-320, the base case (50% probability) targets $230-270, and the bear case (25% probability) targets $150-180. The base case is most likely, assuming modest revenue growth and gradual earnings recovery. The stock is currently at $265.51, which is near the top of the base case range, suggesting limited upside. The key assumption is that the company returns to profitability and delivers EPS growth in line with analyst estimates. If it fails, the stock could fall to the bear case target.
CRL is trading at a PS ratio of 2.51x, which is below the industry average of 3.83x, suggesting it is undervalued on a sales basis. However, the forward PE of 21.45x is not cheap, and the EV/EBITDA of 31.5x is elevated. The PEG ratio of 0.045 implies the market expects high earnings growth, which may or may not materialize. Compared to its own history, the PS ratio is near the low end of its 5-year range, indicating the market is pricing in pessimistic scenarios. Overall, the stock appears fairly valued to slightly undervalued if the earnings recovery is successful, but overvalued if it fails.
CRL is a good buy for investors who believe in a biotech recovery and are willing to accept near-term volatility. The stock has strong momentum, a low PEG ratio of 0.045, and a consensus 'buy' rating, but it trades above the average analyst target of $228.50, implying limited upside. The biggest risk is that the recent earnings loss persists, which could lead to a sharp correction. For long-term investors, the stock could be attractive if the earnings recovery materializes, but for short-term traders, the risk-reward is less favorable at current levels.
CRL is more suitable for long-term investment, given its cyclical nature and the potential for earnings recovery. The stock has a beta of 1.1, indicating higher volatility than the market, which makes it less suitable for short-term trading. The company does not pay a dividend, so returns depend on capital appreciation. With a 1-year price change of +76.6%, the stock has already had a strong run, so short-term entry points may be less attractive. A minimum holding period of 3-5 years is recommended to ride out the biotech cycle and benefit from the company's long-term growth prospects.